dm+d

Unassigned

New Medicines

Previously treated advanced colorectal cancer

Information

New molecular entity
Sumitomo Dainippon Pharma Oncology
Sumitomo Dainippon Pharma Oncology

Development and Regulatory status

Discontinued
Discontinued
Discontinued
May 21Development discontinued [10].

Category

First-in-class stemness inhibitor. Small molecule cancer stem cell inhibitor designed to inhibit cancer stem cell pathways by targeting STAT3.
Colorectal cancer is the third most common cancer in the UK after breast and lung cancer, with approximately 40,000 new cases registered each year. Colorectal cancer is the second most common cause of cancer death in the UK. The age-standardised incidence rate per 100,000 population in the UK in 2008 was 47.2 (29.4 colon, 17.8 rectum). The figures were higher for men than women for both colon and rectal cancers [1].
Previously treated advanced colorectal cancer
Oral

Trial or other data

Feb 21PIII CanStem303C study evaluating efficacy and safety of napabucasin in combination with FOLFIRI with or without bevacizumab in patients with previously treated metastatic colorectal cancer failed to reach the primary endpoints of overall survival [9].